We found that patients with high TMBIM6 expression had poor survival in breast invasive carcinoma (BRCA), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), sarcoma (SARC), and lung adenocarcinoma (LUAD) (Fig. 1g, Supplementary Fig. 1A). The gene discussed is TMBIM6; the disease is endocervical adenocarcinoma.